Prelude Therapeutics Inc
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
PRLD$3.76+4.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows (Unaudited)
STATEMENTS OF CASH FLOWS
| Six months ended June 30, | ||
|---|---|---|
| (in thousands) | 2026 | 2025 |
| Cash flows used in operating activities: | ||
| Net loss | $(24,306) | $(63,316) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 744 | 868 |
| Noncash lease expense | 777 | 767 |
| Stock-based compensation | 4,027 | 7,646 |
| Amortization of premium and discount on marketable securities, net | (701) | (134) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (663) | (1,379) |
| Accounts payable | (2,033) | (2,760) |
| Accrued expenses and other liabilities | (4,681) | (2,098) |
| Deferred revenue | (10,284) | — |
| Operating lease liabilities | (139) | 100 |
| Net cash used in operating activities | (37,259) | (60,306) |
| Cash flows provided by investing activities: | ||
| Purchases of marketable securities | (89,966) | (34,127) |
| Proceeds from maturities of marketable securities | 32,962 | 107,901 |
| Purchases of property and equipment | — | (67) |
| Net cash (used in) provided by investing activities | (57,004) | 73,707 |
| Cash flows used in financing activities: | ||
| Proceeds from issuance of common stock and pre-funded warrants | 90,000 | — |
| Payment of withholding taxes related to stock-based compensation to employees | (64) | (7) |
| Payment of offering costs | (4,661) | — |
| Proceeds from issuance of common stock in connection with the exercise of stock options | 116 | — |
| Proceeds from issuance of common stock under employee stock purchase plan | 115 | 92 |
| Principal payments on finance lease liabilities | — | (208) |
| Net cash provided by (used in) financing activities | 85,506 | (123) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (8,757) | 13,278 |
| Cash, cash equivalents, and restricted cash at beginning of period | 38,491 | 16,518 |
| Cash, cash equivalents, and restricted cash at end of period | $29,734 | $29,796 |
| Supplemental disclosures of non-cash activities: | ||
| Property and equipment in accounts payable and accrued expenses and other current liabilities | $28 | $— |
| Offering costs in accounts payable and accrued expenses and other current liabilities | $60 | $— |
| Unrealized loss on marketable securities | $(235) | $(36) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.